Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research



    SAN FRANCISCO, June 11 /CNW/ -- Jennerex, Inc. (San Francisco, CA and
Ottawa, Canada), a clinical-stage biopharmaceutical company, announced today
that a $10 million grant from the Ontario Institute for Cancer Research (OICR)
has been received by the Centre for Cancer Therapeutics at Ottawa Hospital
Research Institute (OHRI).  A large portion of this grant will fund research
and development in the lab of Dr. John Bell, Jennerex's chief collaborator for
the discovery and development of oncolytic viral therapeutics for cancer
patients.  Funding will support the translation of discoveries into medical
products with the potential to prolong the lives of cancer patients.  The
grant, which provides $10 million (CAD) over four years, will fund the
research and development of novel therapeutics including the development of
Jennerex's oncolytic viral therapy products. Jennerex products have shown
tumor destruction and safety in Phase 1 and 2 clinical trials.

    "We are very pleased that Dr. Bell and Jennerex's oncolytic virus
technologies have been given this vote of confidence by the Ontario Institute
for Cancer Research.  This funding will bolster the translation of Dr. Bell's
promising research into important cancer therapeutics," stated David H. Kirn,
M.D., president and chief executive officer of Jennerex.  "We believe that
there is significant potential in Ontario for medical innovation and
development, and we value our partnerships in Ontario a great deal."

    "This collaboration has been a great example of academia and industry
working together to translate biological research into cutting edge therapies
quickly and effectively," said Dr. John Bell, Senior Scientist at the Ottawa
Hospital Research Institute and Professor of Medicine at the University of
Ottawa.

    Jennerex is conducting Phase 2 clinical trials for several types of
cancer in Ontario, Canada. In addition, the company has a strong and
collaborative relationship with world class investigators at OHRI.  Jennerex
oncolytic virus products are being manufactured in the "Mulcahy Manufacturing
Unit" at OHRI, Ontario's first GMP facility dedicated to oncolytic virus
production. Some of these development costs will be covered by the OICR grant.
 Some of the translational research funding will help support R&D, including
human trials on Jennerex clinical candidates JX-594 and JX-929.
    

    About the Ontario Institute for Cancer Research (OICR)
    
    The OICR is dedicated to research in prevention, early detection,
diagnosis and treatment of cancer.  The Institute is an independent,
not-for-profit corporation funded by the Government of Ontario through the
Ministry of Research and Innovation.
    

    About the Ottawa Hospital Research Institute
    
    The Ottawa Hospital Research Institute (OHRI) is the research arm of The
Ottawa Hospital and is an affiliated institute of the University of Ottawa,
closely associated with the University's Faculties of Medicine and Health
Sciences. The OHRI includes more than 1,300 scientists, clinical
investigators, graduate students, postdoctoral fellows, and staff conducting
research to improve the understanding, prevention, diagnosis and treatment of
human disease. www.ohri.ca
    

    About Jennerex
    
    Jennerex is a clinical-stage biopharmaceutical company focused on the
development and commercialization of first-in-class, breakthrough targeted
oncolytic products for cancer. The company's lead product JX-594, currently in
an international Phase 2 trial for primary liver cancer, demonstrated
promising Phase 1 efficacy and safety results in patients with a diverse array
of common large market cancers. Jennerex's products target, attack and
eradicate cancers through a novel and potent oncolytic mechanism that is
dependent on highly-specific replication of the company's poxviruses in cancer
cells. These products simultaneously stimulate the body's immune response to
the cancer. Of note, this mechanism of action and the results in patients to
date put the company's product class in a leadership position.  Jennerex
Biotherapeutics was established in San Francisco and in Ottawa in 2006 with
Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa
Hospital Research Institute/University of Ottawa. For more information about
Jennerex and the company's robust pipeline and three clinical-stage products,
please visit www.jennerex.com.
    




    




For further information:

For further information: Jennifer Cook Williams of Cook Williams
Communications, Inc., +1-360-668-3701, jennifer@cwcomm.org, for Jennerex, Inc.
Web Site: http://www.jennerex.com                 http://www.ohri.ca

Organization Profile

JENNEREX, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890